男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語(yǔ)Fran?ais
Business
Home / Business / Companies

Sanofi targets ground-breaking therapies with a new R&D strategy

chinadaily.com.cn | Updated: 2022-03-31 11:04
Share
Share - WeChat

Going above and beyond

What will be Sanofi's R&D goals in the coming years? Reed already has concrete plans in mind - the company will expect 8 major submissions in 2022 and 20 more in the next 3 to 5 years in the fields of immunology, oncology, rare blood disorders and vaccines.

"While I take pride in all our accomplishments as an organization, the progress we have made in immunology & inflammation (I&I) is particularly gratifying for me. Our I&I portfolio four years ago was behind the curve compared to our peers. Today, it is arguably one of the most vibrant elements of Sanofi's pipeline with 15 products in development and our flagship medicine growing rapidly in numbers of patients treated. Moreover, our focus on immunoscience at Sanofi has benefited not only the I&I therapeutic area, but it has also served as the foundation for driving progress across our other therapeutic areas, including neurology, hematology, oncology and vaccines."

" Reviewing our success to-date, it's clear that Sanofi is committed to delivering best-in-class innovation, playing to our strengths, and making the necessary deliberate choices about resource allocation to focus our investments on what matters most for patients. Every day, we have the duty to turn great science into new opportunities for patients, and we will continue to do so in 2022."

Diseases are very close to us, and Sanofi is telling us that medical miracles are also very close to us with each of its attempts for scientific breakthroughs.

For pharmaceutical companies, being R&D-driven and placing clinical value first is not just business logic, but a kind of reverence for life, and also the true meaning behind Sanofi's motto of "Chasing the miracles of science to improve people's life".

As Reed said, "News headlines can make scientific advances appear like overnight successes rather than the evolution of hundreds of small discoveries made throughout decades." Sanofi is fully committed to devoting time, resources, and commitment that will be needed in the pursuit of its mission for patients.

|<< Previous 1 2 3   
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 甘孜| 盐津县| 四子王旗| 云安县| 北宁市| 涟源市| 临沧市| 霸州市| 宁都县| 威宁| 吉隆县| 安平县| 巴林左旗| 临澧县| 黔南| 酒泉市| 蒙自县| 县级市| 昌黎县| 阿鲁科尔沁旗| 增城市| 岚皋县| 慈利县| 盘山县| 曲松县| 廉江市| 明水县| 津南区| 布拖县| 茶陵县| 大安市| 兰州市| 当阳市| 托克托县| 延安市| 即墨市| 正定县| 营山县| 景德镇市| 平陆县| 固镇县|